Skip to main content

Table 1

From: Nevirapine (NVP) vs ritonavir-boosted atazanavir (ATV/r) combined with tenofovir/emtricitabine (TDF/FTC) in first-line therapy: NEWART 48-week data

Outcome Measure (48 wks) NVP 200 mg BID (n=75) ATV/r 300/100 QD (n=77) P value Difference (95% CI) from model
adjusting for screening VL and CD4+
Virologic Response (VR) 46 (61.3%) 50 (64.9%) 0.71 -4.1% (-18.3% to 10.1%)
Virologic Failure (VF), Protocol Defined 10 (13.3%) 12 (15.6%) 0.63 -2.6% (-13.1% to 7.9%)
Early withdrawals† 24 18   
- due to investigator-defined VF 5 0   
- due to adverse events 9* 9   
- due to other reason 10 9   
Mean Change in TC/HDLc [baseline to week 48 (LOCF)] -0.38 -0.02 0.038 -0.33 (-0.64 to -0.02)
  1. *NVP arm: 1 DAIDS grade 3 hepatobiliary AE (viral hepatitis); no grade 3/4 rash †2 deaths: 1-NVP (suicide); 1-ATV/r (lymphoma)
  2. For NEWART and ARTEN (combined), VR for NVP 200mg BID was 65% (171/263) vs 65% for ATV/r (176/270) [P=0.75 (CI= -7.7% to 10.7%)].